Head-To-Head Comparison: GRIFOLS S A/S (GRFS) & Arbutus Biopharma (ABUS)

Arbutus Biopharma (NASDAQ: GRFS) and GRIFOLS S A/S (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Valuation & Earnings

This table compares Arbutus Biopharma and GRIFOLS S A/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arbutus Biopharma $10.70 million 49.96 -$84.41 million ($1.79) -5.39
GRIFOLS S A/S $4.88 billion 2.91 $749.04 million $1.10 18.91

GRIFOLS S A/S has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than GRIFOLS S A/S, indicating that it is currently the more affordable of the two stocks.


This table compares Arbutus Biopharma and GRIFOLS S A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arbutus Biopharma -515.00% -75.07% -38.94%
GRIFOLS S A/S 16.55% 17.78% 6.06%

Institutional and Insider Ownership

33.6% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 21.8% of GRIFOLS S A/S shares are owned by institutional investors. 7.6% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


GRIFOLS S A/S pays an annual dividend of $0.39 per share and has a dividend yield of 1.9%. Arbutus Biopharma does not pay a dividend. GRIFOLS S A/S pays out 35.5% of its earnings in the form of a dividend.

Analyst Ratings

This is a summary of recent recommendations for Arbutus Biopharma and GRIFOLS S A/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma 0 3 2 0 2.40
GRIFOLS S A/S 1 3 2 0 2.17

Arbutus Biopharma presently has a consensus price target of $9.50, indicating a potential downside of 1.55%. GRIFOLS S A/S has a consensus price target of $22.00, indicating a potential upside of 5.77%. Given GRIFOLS S A/S’s higher probable upside, analysts clearly believe GRIFOLS S A/S is more favorable than Arbutus Biopharma.

Risk and Volatility

Arbutus Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, GRIFOLS S A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.


GRIFOLS S A/S beats Arbutus Biopharma on 9 of the 14 factors compared between the two stocks.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

GRIFOLS S A/S Company Profile

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply